Literature DB >> 7716542

Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes.

J H Phillips1, J E Gumperz, P Parham, L L Lanier.   

Abstract

Bacterial superantigens bind with high affinity to major histocompatibility complex (MHC) class II antigens on antigen-presenting cells and with T cell antigen receptor (TCR) beta chains on T lymphocytes, which results in the T cell activation responsible for toxic shock syndrome and food poisoning. Many cytotoxic T lymphocyte (CTL) clones were shown to have receptors for human leukocyte antigen (HLA) class I molecules that inhibited superantigen-induced cytotoxicity against appropriate class I-bearing target cells. One type of inhibitory receptor, NKB1, was present on CD4+ and CD8+TCR alpha beta+ CTL clones and blocked the killing of staphylococcal enterotoxin B (SEB)-coated targets bearing certain polymorphic HLA-B molecules. Expression of HLA-A, -B, and -C molecules on the SEB-coated targets also protected against cytolysis mediated by many NKB1-negative T cell clones, suggesting the presence of additional inhibitory MHC class I receptors. These HLA class I receptors may limit tissue destruction and possibly autoimmunity caused by activated T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7716542     DOI: 10.1126/science.7716542

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  62 in total

1.  H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1.

Authors:  M R Daws; M Eriksson; L Oberg; A Ullén; C L Sentman
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

2.  Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor.

Authors:  A Cambiaggi; C Verthuy; P Naquet; F Romagné; P Ferrier; R Biassoni; A Moretta; L Moretta; E Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Finding Balance: T cell Regulatory Receptor Expression during Aging.

Authors:  Mary M Cavanagh; Qian Qi; Cornelia M Weyand; Jörg J Goronzy
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

Review 4.  The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR.

Authors:  Jeroen van Bergen; Frits Koning
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

Review 5.  Pure red cell aplasia associated with type I autoimmune polyglandular syndrome-successful response to treatment with mycophenolate mofetil: case report and review of literature.

Authors:  Milena Bakrac; Vladimir Jurisic; Tanja Kostic; Vera Popovic; Sandra Pekic; Nada Kraguljac; Milica Colovic
Journal:  J Clin Pathol       Date:  2007-01-12       Impact factor: 3.411

Review 6.  Gene expression and generation of CD28-CD8 T cells mediated by interleukin 15.

Authors:  Jason Godlove; Wai Kan Chiu; Nan-ping Weng
Journal:  Exp Gerontol       Date:  2007-01-03       Impact factor: 4.032

7.  Amazonian Amerindians exhibit high variability of KIR profiles.

Authors:  Paloma Daguer Ewerton; Mauro de Meira Leite; Milena Magalhães; Leonardo Sena; Eduardo José Melo dos Santos
Journal:  Immunogenetics       Date:  2007-06-06       Impact factor: 2.846

Review 8.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

9.  Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations.

Authors:  M C Mingari; F Schiavetti; M Ponte; C Vitale; E Maggi; S Romagnani; J Demarest; G Pantaleo; A S Fauci; L Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

10.  Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors.

Authors:  M Valés-Gómez; H T Reyburn; R A Erskine; J Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.